Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

Opinion
Video

Panelists discuss how anti-VEGF therapies have dramatically improved visual outcomes in patients with age-related macular degeneration and diabetic macular edema over the past decade. Key challenges persist, including treatment burden, adherence, and identifying optimal dosing regimens for individual patients.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • Anti-VEGF treatments have been available for age-related macular degeneration and diabetic macular edema for over a decade. Can you discuss how they have impacted patient outcomes and what barriers remain to achieving optimal results?
      Recent Videos
      (Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
      AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
      3 experts are featured in this series.
      Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies
      Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
      Angiogenesis 2025: The global forecast for AI-driven home OCT
      3 experts are featured in this series.
      Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients
      3 experts are featured in this series.
      Perspectives on the Usefulness of Real-world Data
      3 experts are featured in this series.
      Safety Profile of New Therapies
      3 experts are featured in this series.
      Outcomes with Raricimab and Choosing Between the New Therapies
      3 experts are featured in this series.
      Faricimab Molecular Design and Role of Ang-2
      2 experts in this video
      Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases
      3 experts are featured in this series.
      Patient Selection for Aflibercept 8 mg
      Related Content
      Two boxes, labeled "yes" and "no." There is a red checkmark in the "no" box. Concept portraying an ophthalmic clinical trial which does not meet its endpoint. Image credit: ©Matthew Benoit – stock.adobe.com

      Phase 3 COAST trial fails to meet primary endpoints for wet AMD, Opthea reports

      Martin David Harp
      March 24th 2025
      Article

      The Combination OPT-302 with Aflibercept Study (COAST) evaluated sozinibercept 2 mg in combination with aflibercept 2 mg for wet age-related macular degeneration

      PHOTON Results and Their Relation to DME Patients in Your Practice

      PHOTON Results and Their Relation to DME Patients in Your Practice

      July 25th 2024
      Podcast

      John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

      A blue hazard sign, an exclamation point (!) inside a triangle, to communicate the risks of misdiagnosing geographic atrophy and age-related macular degeneration. Image credit: ©jcsnb – stock.adobe.com

      Researchers raise awareness of macular pathologies which mimic AMD and GA

      Lynda Charters
      March 20th 2025
      Article

      Inherited retinal diseases have disease processes distinct from age-related macular degeneration and geographic atrophy, but may present with "phenocopy" clinical signs

      PULSAR Results and Their Relation to nAMD Patients in Your Practice

      PULSAR Results and Their Relation to nAMD Patients in Your Practice

      July 24th 2024
      Podcast

      John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

      An image showing the degeneration of neuron cells. Image credit: ©Corona Borealis – stock.adobe.com

      Cognition Therapeutics announces publication reviewing potential of zervimesine (CT1812) in dry AMD

      Jordana Joy
      March 3rd 2025
      Article

      One in vitro study included in the manuscript was conducted in collaboration with researchers at the University of Southhampton in the United Kingdom

      An illustration of kidneys, in black-and-white, with color over some sections to indicate disease. Image credit: ©Crystal light – stock.adobe.com

      EMA validates indication extension application of pegcetacoplan for treatment of kidney disease

      Hattie Hayes
      February 20th 2025
      Article

      According to Apellis and Sobi, pegcetacoplan (Aspaveli) first received marketing authorisation for treatment of paroxysmal nocturnal hemoglobinuria

      © 2025 MJH Life Sciences

      All rights reserved.